Additional file 1 of Different MAPT haplotypes influence expression of total MAPT in postmortem brain tissue
Creators: name: Tauber, Christina V.
name: Schwarz, Sigrid C.
name: Rösler, Thomas W.
name: Arzberger, Thomas
name: Gentleman, Steve
name: Windl, Otto
name: Krumbiegel, Mandy
name: Reis, André
name: Ruf, Viktoria C.
name: Herms, Jochen
name: Höglinger, Günter U.
Publisher: name: figshare
Year: 2024
Subjects: subject: Genetics
subject: FOS: Biological sciences

description: Additional file 1. Table S1: Title: Demographic, clinical and neuropathologic characteristics of individual postmortem brain donors. Description: The LBD Braak stage and AD Braak and Braak stage each consist of six stages. The CERAD score describes neuritic Amyloid-ß plaques in levels of 0, A, B, C. Lewy inclusion pathology assessed semi-quantitatively the burden of Lewy neurites and Lewy Bodies in the target brain region cortex of fusiform gyrus (+ few, +  + moderate, +  +  + many inclusions). * Since brain stem of this specimen was not available for neuropathological assessment, exclusion of LBD of stage 3 or lower was not possible. Abbreviations: AD, Alzheimer’s disease; bst, brain stem predominant; CERAD, The Consortium to Establish a Registry for Alzheimer’s Disease; C, Control; F, female; CRF, cardiac-respiratory failure; ctx-fg, cortex of fusiform gyrus; CUP, cancer of unknown primary; GI, gastrointestinal; IMP, Imperial College London Brain Bank, LBD, Lewy body disease; limb, limbical; LMU, Neurobiobank of the Ludwig-Maximilians-University of Munich; M, male; n.a. data not available; neo, neocortical; PD, Parkinson’s disease; PMI, postmortem interval; SCLC, small squamous cell lung cancer; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; n.a., not applicable; n.i. no information. Table S2: Title: Cause of death of postmortem brain donors. Description: Abbreviations: Fwd, forward; Rev, reverse; bp, base pairs., chronic obstructive pulmonary disease; CKD, chronic kidney disease; n.a., data not available. Table S3: Title: Primers for MAPT genotyping. Description: Abbreviations: Fwd, forward; Rev, reverse; bp, base pairs. Table S4: Title: RNA integrity values measured in postmortem brain samples. Description: For groupwise comparison of the four subgroups according to MAPT haplotype and disease P-values were calculated using one-way ANOVA. Table S5: Title: Primers for qPCR. Description: Abbreviations: Fwd, forward; Rev, reverse; bp, base pairs; *reference gene; † The used primers for the NSF gene cover NSF, NSF pseudogene and LRRC37A2. A detailed description of primer specificity and possible impact on primer usage can be found in the Materials and Methods section under qPCR. Table S6: Title: Antibodies used for immunoblotting. Description: Abbreviations: Chemi, chemiluminescence; Rb, rabbit; RT, room temperature. Table S7: Title: Proportion of MAPT splice variant mRNA transcripts relative to total MAPT in conditions defined by MAPT haplotype and disease status. Description: For groupwise comparison results were combined according to MAPT haplotype and disease status. P-values were calculated using two-way ANOVA followed by Tukey’s multiple comparisons test. Main effect of haplotype was analyzed by comparison of H1/H1 (Controls + PD) versus H2/H2 (Controls + PD). Main effect of disease was analyzed by comparison of PD (H1/H1 + H2/H2) versus Controls (H1/H1 + H2/H2). The interaction haplotype × disease examined the relationship between the independent variables (haplotype + disease) on the dependent variable of proportions of MAPT transcripts. Data are mean ± SEM. Statistic analysis were not significant for all parameters (P &gt; 0.05). Abbreviations: ctx-fg, cortex of fusiform gyrus; ctx-cbl, cortex of cerebellum. Table S8: Title: Expression of candidate mRNAs in human samples of fusiformis gyrus compared to cerebellum. Description: For the comparison of gene expression between the brain regions, the difference in mRNA levels between gyrus fusiformis and cerebellum were calculated. For groupwise comparison of these differences results were combined according to MAPT haplotype and disease status. P-values were calculated using two-way ANOVA followed by Tukey’s multiple comparisons test and were not significant for all parameters (P &gt; 0.05). Abbreviations: ctx-fg, cortex of fusiform gyrus; ctx-cbl, cortex of cerebellum. Table S9: Title: N-and R-terminal variants of tau protein isoforms relative to total tau in conditions defined by MAPT haplotype and disease status. Description: For groupwise comparison results were combined according to MAPT haplotype and disease status. Statistic analysis for groupwise differences with two-way ANOVA were not significant (P &gt; 0.05) for all parameters. Abbreviations: ctx-fg, cortex of fusiform gyrus; ctx-cbl, cortex of cerebellum. Table S10: Title: Investigation of differences between insoluble and soluble protein levels in human samples of fusiform gyrus and cerebellum. Description: For the comparison of protein levels between the protein fractions, the differences in protein levels between the insoluble and soluble protein fraction were calculated. P-values were calculated using two-way ANOVA followed by Tukey’s multiple comparisons test. Statistic analysis were not significant for all parameters (P &gt; 0.05). Abbreviations: ctx-fg, cortex of fusiform gyrus; ctx-cbl, cortex of cerebellum. Table S11: Title: Regional distribution of different protein levels in human samples of fusiform gyrus related to cerebellum. Description: For the comparison of protein levels between the brain regions, the differences in protein levels between gyrus fusiformis and cerebellum were calculated. For groupwise comparison of these differences results were combined according to MAPT haplotype and disease status. P-values were calculated using two-way ANOVA followed by Tukey’s multiple comparisons test. Abbreviations: ctx-fg, cortex of fusiform gyrus; ctx-cbl, cortex of cerebellum.